Introduction
T h e insulin receptor belongs to the superfamily of transmembrane receptor tyrosine kinases that include the receptors for epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and insulin-like growth factor 1 (IGF-1). All receptors of this family contain an extracellular ligand-binding domain, a transmembrane domain and an intracellular domain with intrinsic tyrosine kinase activity. Binding of ligand to the extracellular domain leads to a conformational change in the intracellular domain resulting in autophosphorylation of the receptor, which in turn activates the receptor tyrosine kinase [1, 2] .
Activation of the insulin receptor kinase by insulin leads to the phosphorylation of a number of intracellular substrates, which include the insulin receptor substrate (IRS) family and Shc. IRS-1 and IRS-2 are crucial for the activation of multiple signalling pathways by the insulin receptor. However, other receptors, such as those for interleukin 4 and some cytokines, are also known to employ the IRS family of docking proteins for their signal transduction [3] , implying the existence of additional signalling pathways that might begin at the level of the insulin receptor. It was originally thought that the direct recruitment of Src homology 2 (SH2)-domain-containing proteins was not an important feature of signalling mechanisms in the insulin/IGF-1 receptor family. However, the discovery of the Grb-10/14 family of adapter proteins revealed that SH2 domain adapter proteins can be recruited directly by the insulin receptor [4-61. A search for other insulin-receptor-interacting proteins led to the identification of SH2-Ba (also known as PSM, for ' proline-rich, SH2 domain mediator') [7- [12] . All members of this family contain a Cterminal SH2 domain, a central P H domain and an N-terminal proline-rich region (Figure 1 ). SH2-B is expressed ubiquitously, whereas the expression of APS is restricted to insulin-sensitive tissues such as adipose tissue, cardiac muscle and skeletal muscle [7,13]. T h e expression of Lnk seems to be restricted to haemopoietic cells [14] . T h e restricted expression of APS, particularly in insulinsensitive cell types, suggested that it might have specific insulin-receptor-signalling functions. All these proteins contain numerous consensus sites for tyrosine and serinelthreonine phosphorylation. Here we review our current understanding of the roles of the adapter proteins APS and SH2-B in insulin receptor signalling.
Interaction of SH2-B with the Fc receptor immunoreceptor tyrosinebased activation motif (ITAM), Janus kinase 2 OAK-2) and the insulin receptor T h e adapter protein SH2-B was first identified as an FceRI ITAM-interacting protein [15] . It was subsequently shown to interact with the insulin receptor activation loop and undergo, albeit weak, insulin-stimulated tyrosine phosphorylation [7] . T h e SH2 domain of SH2-Ba interacts specifically with the activation loop phosphotyrosine residues of the insulin receptor. T h e other SH2-B isoforms, SH2-BP and SH2-By, share common N-termini, P H and SH2 domains but have a distinct Cterminus generated by alternative splicing. It is possible that there are additional splice variants with distinct functions. The alternatively spliced region of SH2-BP and SH2-By varies substantially [12] . T h e C-termini of SH2-BP and SH2-By lack the conserved tyrosine phosphorylation site seen in other members of this family. SH2-BP was identified as a JAK-2-interacting protein [16] in a yeast two-hybrid screen. Co-transfection of SH2-BP with JAK-2 in COS cells has been shown to enhance growth hormone-induced JAK-2 kinase phosphorylation [17] . SH2-BP has been found to be involved in the growth-hormone-induced re-
Figure I Schematic depiction of the SH2-BIAPSILnk family of adapter proteins
Pro, proline-rich region; Y, tyrosine-phosphorylation site; A, deletion; aa, amino acids.
Pro

PH
SH2
Pro ..
SH2-Ba
SHZ-BP
SHZBy
APS
Lnk
organization of actin and in nerve-growth-factorinduced neural differentiation [18] [19] [20] . Because all SH2-B isoforms have a common SH2 domain, it is reasonable to assume that they have the ability to bind the same phosphotyrosine targets. The differences in the C-terminal region might reflect their ability to generate unique signalling complexes. Therefore, although all SH2-B isoforms share the same phosphotyrosine-and phospholipid-binding modules, the signalling complexes generated by each isoform could be distinct. Both SH2-B and APS might be serine/threonine-phosphorylated in the basal state, leading to anomalous migration on SDS/PAGE. The predicted size of SH2-Ba is 79.6 kDa but it migrates with an apparent molecular mass of 98 kDa [7] . Similar anomalous migration is seen with APS, with a predicted size of 68 kDa and an apparent molecular mass of 75 kDa [21, 22] .
Interaction of APS with c-Kit, PDGF and insulin receptors
APS was first identified as a c-Kit-interacting protein during screening of a human B-cell c-DNA library and was found to undergo tyrosine phosphorylation following B-cell antigen receptor (BCR) stimulation [lo] . APS shares considerable sequence similarity with SH2-B in the SH2 domain (80 yo) and the PH domain (58 yo) and to a smaller extent the N-terminal region (33 yo). On the basis of a high sequence similarity in the SH2 domain, we initially hypothesized and later showed that APS interacts with the insulin receptor [21] . Using yeast two-hybrid interaction and glutathione S-transferase ' pulldown ' assays, we found that the activation-loop tyrosine residues 11 58 and 1162 of the insulin receptor were required for its interaction with APS, whereas Tyr-1163 and the C-terminal tyrosine residues were not necessary for the interaction. APS is tyrosine-phosphorylated in response to stimulation with insulin and IGF-1 after receptor activation by the cognate ligand ( Figure 2) [13].
c-Cbl and Grb-2 interact with tyrosine-phosphorylated APS, whereas Shc is associated constitutively [lo] . However, Grb-2 associates constitutively with SH2-B through the prolinerich region between the PH and SH2 domains [18] . In differentiated 3T3-Ll adipocytes, c-Cbl undergoes insulin-stimulated tyrosine phosphorylation, but this does not occur in 3T3-Ll fibroblasts or in Chinese hamster ovary (CHO) cells overexpressing the insulin receptor [23] . We have used several cell lines to analyse the effects of APS and SH2-B overexpression on insulin signalling. Initially APS was overexpressed in the CHO. T cell line that co-expresses insulin receptor under G418 selection. In this cell line the overexpression of APS allows the insulin-stimulated phosphorylation of c-Cbl [22] . In the absence of APS overexpression, stimulation with insulin cannot result in the phosphorylation of c-Cbl despite the high-level expression of the insulin receptor, suggesting that an accessory protein is required to facilitate this. Because APS had previously been shown to interact with c-Cbl [24] , it was likely that the expression of APS would facilitate the recruitment of c-Cbl after stimulation with insulin. This turned out to be true and in fact c-Cbl was found to co-precipitate in a complex with the insulin receptor and APS [22] . Thus, in contrast with other tyrosine kinase receptors, the insulin receptor requires an accessory protein to interact with c-Cbl.
The proto-oncogene product c-Cbl is a large cytoplasmic protein comprising a variant SH2 domain, a RING finger domain, many SH3-domain-binding motifs and several potential tyrosine phosphorylation sites [25] . It interacts directly through its variant SH2 domain with several phosphorylated receptor tyrosine kinases including the receptors for PDGF, E G F and colonystimulating factor 1 [25, 26] . c-Cbl promotes the ubiquitination of tyrosine kinase receptors by functioning as a RING-type E2-dependent ubiquitin protein ligase [27] . We found that transfection of APS facilitated insulin-stimulated cCbl recruitment and ubiquitination of the insulin receptor /?-subunit [22] . This ubiquitination might facilitate either endocytosis or degradation of the receptor.
Thus it seems that there are two mechanisms for the interaction of the insulin receptor with the c-Cbl proto-oncogene product. First, there is the c-Cbl-associated protein, CAP, that interacts constitutively with the insulin receptor [28, 29] in a ligand-independent manner. In common with APS, CAP is expressed in differentiated adipocytes but not in precursor fibroblasts. In contrast, APS is recruited to the activated autophosphorylated receptor and thus this recruitment mechanism is ligand-dependent and autophosphorylation-dependent. It is not clear whether CAP also facilitates the ubiquitination of the insulin receptor or associated molecules.
Both c-Cbl and Grb-2 are thought to interact with the C-terminal phosphotyrosine of APS [18] but it is not known which protein binds with and Grb-2, generates unique signalling complexes that associate directly with the insulin receptor ( Figure 3 ). APS-mediated complexes in oivo might include APS-Grb-2 and/or APS-Cbl, although it is not clear which is the predominant complex. However, at present the significance of these complexes in insulin receptor signalling and any potential crosstalk between the APS-generated complexes and the IRS or Shc complexes is not known and will require further investigation.
T h e tyrosine phosphorylation of APS in response to insulin in 3T3-Ll adipocytes is rapid (Figure 2 ). Insulin-stimulated tyrosine phosphorylation of APS can be detected within 30 s of stimulation with insulin. Because APS interacts with the activation loop, one could speculate that this is probably the first protein-protein inter- action of the activated insulin receptor and might even precede the interaction of the receptor with the IRS proteins. In CHO. T cells stably expressing APS, APS phosphorylation can be detected in the whole-cell lysate, suggesting that the phosphorylation is of high stoichiometry [22] . Indeed, APS has several consensus sites for both tyrosine phosphorylation and serinelthreonine phosphorylation. T h e major tyrosine-phosphorylation site has been reported to be Tyr-618 on the basis of the results of site-directed mutagenesis of the C-terminal tyrosine [13] . This C-terminal tyrosine has been found to be important for the interaction with c-Cbl [24] . Phosphorylation of APS on this tyrosine residue allows it to bind to the variant SH2 domain of c-Cbl. In contrast, SH2-Ba seems to be a very weak substrate for the insulin receptor ; the phosphorylation of SH2-Ba is of low stoichiometry [7] . T h e structural basis for this is not clear but might arise because of differences in the P H domain that would determine the ability of APS and SH2-Ba to be recruited to the cell membrane after stimulation with insulin.
Interestingly, whereas the ubiquitination of receptor tyrosine kinases acts as a negative regulatory mechanism to attenuate tyrosine kinase receptor signalling, our preliminary studies reveal that the overexpression of APS or SH2-Ba leads to an enhancement of insulin-stimulated signalling. APS causes a shift in the dose response for the insulin-stimulated tyrosine phosphorylation and activation of Akt and the ERK/MAP kinase pathways. Thus APS displays a unique ability to act both as a substrate for the insulin receptor and as a regulator of its tyrosine kinase activity. This 
